A comparison of cost-effectiveness of three protocols for diagnosis and treatment of gonococcal and chlamydial infections in women in Africa

Sexually Transmitted Diseases

Volumn 30, Issue 5, 2003, Pages 455-469

  Sahin Hodoglugil, Nuriye Nalan ^a,b   Woods, Rebecca ^a   Pettifor, Audrey ^a   Walsh, Julia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; KANAMYCIN; NORFLOXACIN; OFLOXACIN; SPECTINOMYCIN; TETRACYCLINE;

AFRICA; ARTICLE; CHLAMYDIASIS; CLINICAL FEATURE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; ENZYME IMMUNOASSAY; EPIDEMIOLOGICAL DATA; FEMALE; GONORRHEA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MEDICAL STAFF; MONTE CARLO METHOD; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREVALENCE; TREATMENT OUTCOME; UTERINE CERVICITIS;

ADOLESCENT; ADULT; AFRICA; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIACEAE INFECTIONS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DECISION TREES; DOXYCYCLINE; FEMALE; GONORRHEA; HUMANS; MULTIVARIATE ANALYSIS; UTERINE CERVICITIS;

EID: 0038193852     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200305000-00014     Document Type: Article

References (90)

1. Dallabetta G, Laga M, Lamptey P, eds. Control of Sexually Transmitted Diseases: A Handbook for the Design and Management of Programs. Arlington: AIDSCAP/Family Health International, 1996.
2. Gerbase A, Rowley J, Heymann D, Berkley S, Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998; 74(Suppl 1):S12-S16.
3. Lamptey P. Sexually transmitted infections in sub-Saharan Africa: HIV brings much needed attention to a hidden problem. AIDS Infothek (Switzerland) 2000.
4. Fleming D, Wasserheit J. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
5. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-536.
6. Wawer M, Sewankambo N, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525-535.
7. Wawer M, Sewankambo N, Serwadda D, Gray R. Authors' reply. Lancet 1999; 353:1523-1524.
8. Nicoll A, Johnson A, Adler M, Laga M. Preventing HIV-1: lessons from Mwanza and Rakai. Lancet 1999; 353:1522.
9. Matthys F, Boelaert M. Letter to the editor. Lancet 1999; 353:1523.
10. Hitchcock P, Fransen L. Preventing HIV infection: lessons from Mwanza and Rakai. Lancet 1999; 353:513-515.
11. Hudson C. Community-based trials of sexually transmitted disease treatment: repercussions for epidemiology and HIV prevention. Bull World Health Organ 2001; 79:48-58.
12. Piot P, Rowley J. Economic impact of reproductive tract infections and resources for their control. In: Germain A, Holmes K, Piot P, Wasserheit J, eds. Reproductive Tract Infections: Global Impact and Priorities for Women's Reproductive Health. New York: Plenum Press, 1992:227-248.
13. Watts C, Kumaranayake L. Thinking big: scaling-up HIV-1 interventions in sub-Saharan Africa. Lancet 1999; 354:1492.
14. World Health Organization. An Overview of Selected Curable Sexually Transmitted Diseases. Geneva: World Health Organization, 1997.
15. Quinn T. Recent advances in diagnosis of sexually transmitted diseases. Sex Transm Dis 1994; 21(Suppl 2):S19-S27.
16. World Health Organization. Management of Sexually Transmitted Diseases. Geneva: UNAIDS, World Health Organization, 1997.
17. World Health Organization. Guidelines for the Management of Sexually Transmitted Diseases. Geneva: World Health Organization, 2001 (WHO/RHR/01.10).
18. Brabin L. Clinical management and prevention of sexually transmitted diseases: a review focusing on women. Acta Trop 2000;75:53-70.
19. Pettifor A, Walsh J, Wilkins V, Raghunathan P. How effective is syndromic management of STDs? A review of current studies. Sex Transm Dis 2000;27:371-385.
20. Van der Veen F, Fransen L. Drugs for STD management in developing countries: choice, procurement, cost, and financing. Sex Transm Infect 1998; 74(supplement 1):S166-S174.
21. Wilkinson D, Connolly A, Harrison A, Lurie M, Abdool Karim S. Sexually transmitted disease syndromes in rural South Africa: results from health facility surveillance. Sex Transm Dis 1998; 25:20-23.
22. Over M, Piot P. HIV infection and sexually transmitted diseases. In: Jamison D, ed. Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993.
23. Hoffman M, Pick W, Cooper D, Myers J. Women's health status and use of health services in a rapidly growing peri-urban area of South Africa. Soc Sci Med 1997; 45:149-157.
24. Maggwa N, Askew I, Simba S, et al. Demand for and Cost-Effectiveness of Integrating RTI/HIV Services with Clinic-Based Family Planning Services in Zimbabwe. Zimbabwe: The Population Council, 1999.
25. Soderlund N, Lavis J, Broomberg J, Mills A. The costs of HIV prevention strategies in developing countries. Bull World Health Organ 1993; 71:595-604.
26. Schwartlander B, Stover J, Walker N, et al. Resource needs for HIV/AIDS. Science 2001; 292:2434-2436.
27. Paavonen J, Puolakkainen M, Paukku M, Sintonene H. Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program. Obstet Gynecol 1998; 92:292-297.
28. Mukenge-Tshibaka L, Alary M, Bernier F, et al. Diagnostic performance of the Roche AMPLICOR PCR in detecting Neisseria gonorrhea in genitourinary specimens from female sex workers in Cotonou, Benin. J Clin Microbiol 2000; 38:4076-4079.
29. Farrell D. Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB nested PCR and 16S rRNA PCR. J Clin Microbiol 1999; 37:386-390.
30. La Ruche G, Lorougnon F, Digbeu N. Therapeutic algorithms for the management of sexually transmitted diseases at the peripheral level in Cote d'Ivoire: assessment of efficacy and cost. Bull World Health Organ 1995; 1995:305-313.
31. Ossewaarde J, Plantema F, Rieffe M, Nawrocki R, De Vries A, Van Loon A. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis 1992; 11:693-697.
32. Martin D, Mroczkowski T, Dalu Z, et al. A controlled trial of single dose of azithromycin for the treatment of chlamydia urethritis and cervicitis: the Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992; 327:921-925.
33. Bandolier. Chlamydial STD Treatment. http//www.jr2.ox.ac.uk/bandolier/band28/b28-4.html. 1996.
34. World Health Organization. Essential drugs: WHO model list [revised December 1999]. WHO Drug Information 1999; 13:249-262.
35. Haddix A, Hillis S, Kassler W. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995;22:274-280.
36. Marra F, Marra C, Patrick D. Cost effectiveness analysis of azithromycin and doxycycline for Chlamydia trachomatis infection in women: a Canadian perspective. Canadian J Infect Dis 1997; 8:202-208.
37. Bachmann L, Stephens J, Richey C, Hook E. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26:279-280.
38. Magid D, Douglas J, Schwartz S. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399.
39. Mayaud P, Uledi E, Comelissen J, et al. Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. Sex Transm Infect 1998; 74(Suppl 1):S139-S146.
40. African Networks for Health Research and Development. AFRONETS Archives (http://www.afronets.org/archive/200105/). 2001.
41. OutLook. STD Control and Primary Health Care for Women: Experience and Challenges (http://www.path.org/outlook/html/15_2.htm#std). 1997.
42. Vrcic H, Zovko V, Culig J. Economic burden of STD in Croatia: incremental cost effectiveness analysis of azithromycin vs. doxycycline for treating Chlamydia trachomatis genital infections in women. In: Proceedings of ICMAS, Seville, Spain, 2000.
43. Wilkinson D. Syndromic management of sexually transmitted diseases in developing countries: what role in the control of the STD and HIV epidemics? Genitourin Med 1997; 73:427-428.
44. Connolly C, Wilkinson D, Harrison A. Inadequate treatment for sexually transmitted diseases in the South African private health sector. Int J STD AIDS 1999; 10:324-327.
45. Harrison A, Wilkinson D, Lurie M, Connoly A, Abdool Karim S. Improving quality of sexually transmitted disease case management in rural South Africa. AIDS 1998; 12:2329-2335.
46. Wilkinson D, Rutherford G. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Review (http://www.update-software.com/abstracts/ab001220.htm). 2002.
47. Walker D, Muyinda H, Foster S, Kengeya-Kayondo J, Whitworth J. The quality of care by private practitioners for sexually transmitted diseases in Uganda. Health Policy and Planning 2001; 16:35-40.
48. Hudeson C, Smith A. Ethics of mass STD treatment. Lancet 2000; 356:1115.
49. Hayes R, Wawer M, Gray R, et al. Randomised trials of STD treatment for HIV prevention: report of an international workshop. Genitourin Med 1997; 73:432-443.
50. Van Dam J. Hybrid STI interventions: putting new prevention and treatment approaches to the test. http://www.popcouncil.org/horizons/newsletter/horizons(1)_2.html. 2000.
51. Steen R, Dallabetta G. The use of epidemiologic mass treatment and syndrome management for sexually transmitted disease control. Sex Transm Dis 1999; 26(Suppl 4):S12-S20.
52. Van Dam C, Becker K, Ndowa F, Islam M. Syndromic approach to STD case management: where do we go from here? Sex Transm Infect 1998; 74(Suppl 1):S175-S178.
53. Dallabetta G, Feinberg M. Efforts to control sexually transmitted diseases as a means to limit HIV transmission: pros and cons. Curr Infect Dis Rep 2001; 3:162-168.
54. Steen R, Vuylsteke B, DeCoito T, et al. Evidence of declining STD revalence in a South African mining community following a coregroup intervention. Sex Transm Dis 2000; 27:9-11.
55. Wilkinson D, Abdool Karim S, Harrison A, et al. Unrecognized sexually transmitted infections in rural South African women: a hidden epidemic. Bull World Health Organ 1999; 77:22-28.
56. Colvin M, Abdool Karim S, Connolly C, Hoosen A, Ntuli N. HIV infection and asymptomatic sexually transmitted infections in a rural South African community. Int J STD AIDS 1998; 9:548-550.
57. Fonck K, Mwai C, Rakwar J, Kiuri P, Ndinya-Achola J, Temmerman M. Healthcare-seeking behavior and sexual behavior of patients with sexually transmitted diseases in Nairobi, Kenya. Sex Transm Dis 2001; 28:367-371.
58. Chesson H, Pinkerton S. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr 2000; 24:48-56.
59. Williams B, Gouws E. The epidemiology of human immunodeficiency virus in South Africa. The Royal Society of Philosophy. Trans R Soc Trop Med Hyg 2001; 356:1077-1086.
60. Dietrich M, Hoosen A, Moodley J, Moodley S. Urogenital tract infections in pregnancy at King Edward VIII Hospital, Durban, South Africa. Genitourin Med 1992; 68:39-41.
61. Wilkinson D, Ndovela N, Harrisson A, Lurie M, Connolly C, Sturm A. Family planning services in developing countries: an opportunity to treat asymptomatic and unrecognised genital tract infections? Genitourin Med 1997; 73:558-560.
62. Schneider H, Coetzee D, Fehler H, et al. Screening for sexually transmitted diseases in rural South African women. Sex Transm Infect 1998; 74(Suppl 1):S147-S152.
63. Pham-Kanter G, Steinberg M, Ballard R. Sexually transmitted diseases in South Africa. Genitourin Med 1996; 72:160-171.
64. Diallo M, Ghys P, Vuylsteke B, et al. Evaluation of simple diagnostic algorithms for Neisseria gonorrhoeae and Chlamydia trachomatis cervical infections in female sex workers in Abijan, Cote d'Ivoire. Sex Transm Infect 1998; 74(Suppl 1):S106-S111.
65. Laga M, Nzanze H, Brunham R, et al. Epidemiology of ophthalmia neonatorum in Kenya. Lancet 1986; November 15:1145-1148.
66. Vuylsteke B, Laga M, Alary M, et al. Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. Clin Infect Dis 1993; 17:82-88.
67. Daly C, Franco L, Chilongozi D, Dallabetta G. A cost comparison of approaches to sexually transmitted disease treatment in Malawi. Health Pol Plan 1998; 13:87-93.
68. Gray R, Wawer M, Sewankambo N, et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases in Rakai District, Uganda. AIDS 1999; 13:2113-2123.
69. Paxton L, Sewankambo N. Gray R, et al. Asymptomatic non-ulcerative genital tract infections in a rural Ugandan population. Sex Transm Infect 1998; 74:421-425.
70. Paxton L, Kiwanuka N, Nalugoda F, Gray R, Wawer M, Group RPS. Community based study of treatment seeking among subjects with symptoms of sexually transmitted disease in rural Uganda. BMJ 1998; 317:1630-1631.
71. UNAIDS, World Health Organization. Consultation on STD interventions for preventing HIV: what is the evidence? Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization, 2001 (report no. UNAIDS/01.81E - WHO/HSI/2000.02).
72. Korenromp E, Van Vliet C, Grosskurth H, et al. Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 2000; 14:573-593.
73. Grosskurth H, Mwijarubi E, Todd J, et al. Operational performance of an STD control programme in Mwanza Region, Tanzania. Sex Transm Infect 2000; 76:426-436.
74. Hanson S, Sunkutu RM, Kamanga J, Höjer B, Sandström E. STD care in Zambia: an evaluation of the guidelines for case management through a syndromic approach. Intl J STD AIDS 1996; 7:324-332.
75. Mehta S, Bishai D, Howell M, Rothman R, Quinn T, Zenilman J. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83-91.
76. Parks K, Dixon P, Richey C, Hook E. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis 1997; 24:229-235.
77. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000; 355:1981-1987.
78. Mayaud P, ka-Gina G, Cornelissen J, et al. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex Transm Infect 1998; 74(Suppl 1):S77-S84.
79. Marseille E, Kahn J, Billinghurst K, Saba J. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. Soc Sci Med 2001; 52:131-148.
80. Harrison A, Abdool Karim S, Floyd K, et al. Syndrome packets and health worker training improve sexually transmitted disease case management in rural South Africa: randomized controlled trial. AIDS 2000; 14:2769-2779.
81. Mayaud P, Ka-Gina G, Grosskurth H. Effectiveness, impact and cost of syndromic management of sexually transmitted diseases in Tanzania. Int J STD AIDS 1998; 9(Suppl 1):11-4.
82. Gilson L, Mkanje R, Grosskurth H, et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet 1997; 350:1805-1809.
83. Bulut A. Cost benefit analysis of sexually transmitted diseases. FEMS Immunol Med Microbiol 1999; 24:461-467.
84. Kumaranayake L, Watts C. Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa. AIDS 2000; 14(suppl 3):S239-S252.
85. Hillis S. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women: a use-effectiveness study in public health settings. Sex Transm Dis 1998; 25:5-11.
86. PreMeC Bulletin. Azithromycin (zithromax) in genital Chlamydia (http//www.premec.org.nz/bulletins/77.htm) 1999.
87. South African Department of Health. Preliminary Report: STDs in North West Province (http://196.36.153.56/doh/docs/reports/1999/nwfinal-app2.pdf). 1998.
88. Parker K, Koumans E, Hawkins R, et al. Providing low-cost sexually transmitted disease services in two semi-urban health centers in Central African Republic (CAR): characteristics of patients and patterns of health seeking behavior. Sex Transm Dis 1999; 26:508-516.
89. Medical Corps. Anthrax Drugs of Choice (http://medicalcorps.org/p12.html). 2002.
90. Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers (http://data.bls.gov/servlet/SurveyOutputServlet). 2002.